754 related articles for article (PubMed ID: 16333862)
1. Bone marrow transplantation from matched related donors for patients with Fanconi anemia using low-dose busulfan and cyclophosphamide as conditioning.
Torjemane L; Ladeb S; Ben Othman T; Abdelkefi A; Lakhal A; Ben Abdeladhim A
Pediatr Blood Cancer; 2006 Apr; 46(4):496-500. PubMed ID: 16333862
[TBL] [Abstract][Full Text] [Related]
2. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
3. Unrelated donor bone marrow transplantation in Fanconi anaemia: the Leiden experience.
Zwaan CM; Van Weel-Sipman MH; Fibbe WE; Oudshoorn M; Vossen JM
Bone Marrow Transplant; 1998 Mar; 21(5):447-53. PubMed ID: 9535036
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow transplantation from matched siblings in patients with fanconi anemia utilizing low-dose cyclophosphamide, thoracoabdominal radiation and antithymocyte globulin.
Ayas M; Solh H; Mustafa MM; Al-Mahr M; Al-Fawaz I; Al-Jefri A; Shalaby L; Al-Nasser A; Al-Sedairy R
Bone Marrow Transplant; 2001 Jan; 27(2):139-43. PubMed ID: 11281382
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow transplantation in thalassemia major patients using "short" anti-thymocyte globulin therapy in Shiraz, Southern Iran.
Zakerinia M; Khojasteh HN; Ramzi M; Haghshenas M
Transplant Proc; 2005 Dec; 37(10):4477-81. PubMed ID: 16387149
[TBL] [Abstract][Full Text] [Related]
6. Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection.
Dulley FL; Vigorito AC; Aranha FJ; Sturaro D; Ruiz MA; Saboya R; Macedo MC; Da Silva RL; Chamone DA; Mehta J; Bacigalupo A; De Souza CA
Bone Marrow Transplant; 2004 Jan; 33(1):9-13. PubMed ID: 14578930
[TBL] [Abstract][Full Text] [Related]
7. Low-dose cyclophosphamide conditioning for haematopoietic cell transplantation from HLA-matched related donors in patients with Fanconi anaemia.
Zanis-Neto J; Flowers ME; Medeiros CR; Bitencourt MA; Bonfim CM; Setúbal DC; Funke V; Sanders J; Deeg HJ; Kiem HP; Martin P; Leisenring W; Storb R; Pasquini R
Br J Haematol; 2005 Jul; 130(1):99-106. PubMed ID: 15982351
[TBL] [Abstract][Full Text] [Related]
8. Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity.
Bertz H; Potthoff K; Mertelsmann R; Finke J
Bone Marrow Transplant; 1997 Jun; 19(12):1169-73. PubMed ID: 9208109
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy.
Klein JL; Avalos BR; Belt P; Taylor CA; Ezzone SA; Scholl MD; Fisher J; Young D; Copelan EA
Bone Marrow Transplant; 1996 Apr; 17(4):479-83. PubMed ID: 8722342
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine-based conditioning for allogeneic stem cell transplantation for multiply transfused patients with Fanconi's anemia.
George B; Mathews V; Shaji RV; Srivastava V; Srivastava A; Chandy M
Bone Marrow Transplant; 2005 Feb; 35(4):341-3. PubMed ID: 15640819
[TBL] [Abstract][Full Text] [Related]
11. The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases.
Rosales F; Peylan-Ramu N; Cividalli G; Varadi G; Or R; Naparstek E; Slavin S; Nagler A
Bone Marrow Transplant; 1999 May; 23(9):861-5. PubMed ID: 10338039
[TBL] [Abstract][Full Text] [Related]
12. Fludarabine, low-dose busulfan and antithymocyte globulin as conditioning for Fanconi anemia patients receiving bone marrow transplantation from HLA-compatible related donors.
Maschan AA; Trakhtman PE; Balashov DN; Shipicina IP; Skorobogatova EV; Skvortsova YV; Dyshlevaja ZM; Samochatova EV; Rumiantsev AG
Bone Marrow Transplant; 2004 Aug; 34(4):305-7. PubMed ID: 15195080
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic stem cell transplantation in patients with Fanconi's anemia and myelodysplasia or leukemia utilizing low-dose cyclophosphamide and total body irradiation.
Ayas M; Al-Jefri A; Al-Mahr M; Rifai S; Moussa E; Karaoui M; Roberts G; El-Solh H
Bone Marrow Transplant; 2004 Jan; 33(1):15-7. PubMed ID: 14578932
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow transplantation for Fanconi anemia using fludarabine-based conditioning.
Stepensky P; Shapira MY; Balashov D; Trakhtman P; Skorobogatova E; Rheingold L; Brooks R; Revel-Vilk S; Weintraub M; Stein J; Maschan A; Or R; Resnick IB
Biol Blood Marrow Transplant; 2011 Sep; 17(9):1282-8. PubMed ID: 21220033
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin.
Kröger N; Zabelina T; Renges H; Krüger W; Kordes U; Rischewski J; Schrum J; Horstmann M; Ayuk F; Erttmann R; Kabisch H; Zander AR
Ann Hematol; 2002 Nov; 81(11):627-31. PubMed ID: 12454700
[TBL] [Abstract][Full Text] [Related]
16. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Ball E; Cook D; Andresen S; Kuczkowski E; Bolwell B
Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients.
van Besien K; Thall P; Korbling M; Pugh WC; Khouri I; Mehra R; Giralt S; Anderlini P; Amin K; Mirza N; Seong D; Gajewski J; Hester J; Andersson B; Cabanillas F; Champlin R; Przepiorka D
Biol Blood Marrow Transplant; 1997 Aug; 3(3):150-6. PubMed ID: 9310192
[TBL] [Abstract][Full Text] [Related]
18. Stem cell transplantation for patients with Fanconi anemia with low-dose cyclophosphamide and antithymocyte globulins without the use of radiation therapy.
Ayas M; Al-Jefri A; Al-Mahr M; Rifai S; Al-Seraihi A; Tbakhi A; Mustafa M; Khairy A; Moussa E; Iqbal A; Shalaby L; El-Solh H
Bone Marrow Transplant; 2005 Mar; 35(5):463-6. PubMed ID: 15654354
[TBL] [Abstract][Full Text] [Related]
19. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen.
Matsuyama T; Kojima S; Kato K
Bone Marrow Transplant; 1998 Jul; 22(1):21-6. PubMed ID: 9678791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
